We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pharma to FDA: Limit or Spell Out Use of Covariates in Randomized Trials
Pharma to FDA: Limit or Spell Out Use of Covariates in Randomized Trials
The FDA should limit or at least spell out the different kinds of covariates allowed in randomized trials, a pair of drug industry giants told the agency.